Advertisement

World Journal of Surgery

, Volume 38, Issue 9, pp 2395–2402 | Cite as

Antiviral Therapy Decreases Recurrence of Hepatitis B Virus-related Hepatocellular Carcinoma after Curative Resection: A Meta-analysis

  • Yanming Zhou
  • Zhansai Zhang
  • Yanfang Zhao
  • Lupeng Wu
  • Bin Li
Article

Abstract

Background

The long-term outcome after curative resection of hepatocellular carcinoma (HCC) remains unsatisfactory because of the high incidence of recurrence. The present study was intended to assess the impact of hepatitis B virus (HBV) DNA level and nucleos(t)ide analog therapy on posthepatectomy recurrence of HBV-related HCC.

Methods

Eligible studies were identified through a computerized literature search. The pooled relative risk ratio (RR) with 95 % confidence interval (CI) was calculated using Review Manager 5.1 Software.

Results

Twenty studies with a total of 8,204 participants were included for this meta-analysis. Pooled analysis showed that high viral load was significantly associated with risk of recurrence (RR: 1.85, 95 % CI: 1.41–2.42; P < 0.001), poorer disease-free survival (DFS) (RR: 1.96, 95 % CI: 1.62–2.38; P < 0.001), and poorer overall survival (OS) (RR: 1.47, 95 % CI: 1.22–1.77; P < 0.001) of HBV-related HCC after surgical resection. Nucleos(t)ide analog therapy significantly decreased the recurrence risk (RR: 0.69, 95 % CI: 0.59–0.80; P < 0.001) and improved both DFS (RR: 0.70, 95 % CI: 0.58–0.83; P < 0.001) and OS (RR: 0.46, 95 % CI: 0.32–0.68; P < 0.001).

Conclusions

High DNA level is associated with posthepatectomy recurrence of HBV-related HCC. Nucleos(t)ide analog therapy improves the prognosis of HBV-related HCC after resection.

Keywords

Overall Survival Risk Ratio High Viral Load Telbivudine Poor Overall Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRefGoogle Scholar
  2. 2.
    Papatheodoridis GV, Lampertico P, Manolakopoulos S et al (2010) Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 53:348–356PubMedCrossRefGoogle Scholar
  3. 3.
    Zhou Y, Sui C, Li B et al (2010) Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol 8:55PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Tung-Ping Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Hung IF, Poon RT, Lai CL et al (2008) Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 103:1663–1673PubMedCrossRefGoogle Scholar
  6. 6.
    Kim BK, Park JY, Kim do Y et al (2008) Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 28:393–401PubMedCrossRefGoogle Scholar
  7. 7.
    Kubo S, Tanaka H, Takemura S et al (2007) Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 37:94–100PubMedCrossRefGoogle Scholar
  8. 8.
    Piao CY, Fujioka S, Iwasaki Y et al (2005) Lamivudine treatment in patients with HBV-related hepatocellular carcinoma—using an untreated, matched control cohort. Acta Med Okayama 59:217–224PubMedGoogle Scholar
  9. 9.
    Kuzuya T, Katano Y, Kumada T et al (2007) Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 22:1929–1935PubMedCrossRefGoogle Scholar
  10. 10.
    Chuma M, Hige S, Kamiyama T et al (2009) The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 44:991–999PubMedCrossRefGoogle Scholar
  11. 11.
    Koda M, Nagahara T, Matono T et al (2009) Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 48:11–17PubMedCrossRefGoogle Scholar
  12. 12.
    Li N, Lai EC, Shi J et al (2010) A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 17:179–185PubMedCrossRefGoogle Scholar
  13. 13.
    Chan AC, Chok KS, Yuen WK et al (2011) Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 146:675–681PubMedCrossRefGoogle Scholar
  14. 14.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessment the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRefGoogle Scholar
  15. 15.
    Simillis C, Constantinides VA, Tekkis PP et al (2007) Laparoscopic versus open hepatic resections for benign and malignant neoplasms—a meta-analysis. Surgery 141:203–211PubMedCrossRefGoogle Scholar
  16. 16.
    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRefGoogle Scholar
  17. 17.
    Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Cai X, Huang C, Zhou H et al (2008) Postoperative serum HBV DNA level evaluate the recurrence after radical resection for patients with HBV-related hepatocellular carcinoma [in Chinese]. J Fujian Med Univ 42:438–440Google Scholar
  19. 19.
    Wu JC, Huang YH, Chau GY et al (2009) Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 51:890–897PubMedCrossRefGoogle Scholar
  20. 20.
    An HJ, Jang JW, Bae SH et al (2010) Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 25:1876–1882PubMedCrossRefGoogle Scholar
  21. 21.
    Qu LS, Jin F, Huang XW et al (2010) High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg 14:1111–1120PubMedCrossRefGoogle Scholar
  22. 22.
    Yang M, Xiao L, Shi X (2010) A study of antiviral therapy in prevention of tumor recurrence after curative treatment of hepatocellular carcinoma [in Chinese]. Med J Chin PLA 35:726–732Google Scholar
  23. 23.
    Yeh CT, So M, Ng J et al (2010) Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma. Hepatology 52:1922–1933PubMedCrossRefGoogle Scholar
  24. 24.
    Cheng F, Lv L, Sun B et al (2011) A study of antiviral therapy in prevention of tumor recurrence after radical liver resection of hepatocellular carcinoma with high load of hepatitis B virus DNA [in Chinese]. Acta Univ Med Nanjing 31:882–888Google Scholar
  25. 25.
    Choi JG, Chung YH, Kim JA et al (2012) High HBV-DNA titer in surrounding liver rather than in hepatocellular carcinoma tissue predisposes to recurrence after curative surgical resection. J Clin Gastroenterol 46:413–419PubMedCrossRefGoogle Scholar
  26. 26.
    Feng J, Li J, Fang T et al (2012) The effect of adefovir dipivoxil on the prognosis of HBV positive hepatocellular carcinoma [in Chinese]. China Modern Doctor 50:50–54Google Scholar
  27. 27.
    Urata Y, Kubo S, Takemura S et al (2012) Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 19:685–696PubMedCrossRefGoogle Scholar
  28. 28.
    Wu CY, Chen YJ, Ho HJ et al (2012) Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906–1914PubMedCrossRefGoogle Scholar
  29. 29.
    Yang T, Lu JH, Zhai J et al (2012) High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol 38:683–691PubMedCrossRefGoogle Scholar
  30. 30.
    Su CW, Chiou YW, Tsai YH et al (2013) The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. PLoS One 8:e66457PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Yin J, Li N, Han Y et al (2013) Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 31:3647–3655PubMedCrossRefGoogle Scholar
  32. 32.
    Zhang Z, Geng X, Zhao H et al (2013) The clinical significance of antiviral therapy for hepatocellular carcinoma with positive HBV-DNA patients [in Chinese]. J Hepatobiliary Surg 21:177–180Google Scholar
  33. 33.
    Tsai WL, Chung RT (2010) Viral hepatocarcinogenesis. Oncogene 29:2309–2324PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Manigold T, Rehermann B (2003) Chronic hepatitis B and hepatocarcinogenesis: does prevention of “collateral damage” bring the cure? Hepatology 37:707–710PubMedCrossRefGoogle Scholar
  35. 35.
    Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73PubMedCrossRefGoogle Scholar
  36. 36.
    Mendy ME, Welzel T, Lesi OA et al (2010) Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 17:115–122PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207PubMedCrossRefGoogle Scholar
  38. 38.
    Breitenstein S, Dimitroulis D, Petrowsky H et al (2009) Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 96:975–981PubMedCrossRefGoogle Scholar
  39. 39.
    Lin SM, Sheen IS, Chien RN et al (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971–975PubMedCrossRefGoogle Scholar
  40. 40.
    Lo CM, Liu CL, Chan SC et al (2007) A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245:831–842PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Chen LT, Chen MF, Li LA et al (2012) Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 255:8–17PubMedCrossRefGoogle Scholar
  42. 42.
    Wong JS, Wong GL, Tsoi KK et al (2011) Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 33:1104–1112PubMedCrossRefGoogle Scholar
  43. 43.
    Qu LS, Liu JX, Kuai XL, et al (2013) Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: a meta-analysis. Hepatol Res. doi:  10.1111/hepr.12172
  44. 44.
    Chung GE, Kim W, Lee JH et al (2011) Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. J Gastroenterol Hepatol 26:1638–1645PubMedCrossRefGoogle Scholar
  45. 45.
    Zhou Y, Zhao Y, Li B et al (2010) Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol 10:78PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    McKay A, Mackenzie S, Sutherland FR et al (2006) Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy. Br J Surg 93:929–936PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2014

Authors and Affiliations

  • Yanming Zhou
    • 1
  • Zhansai Zhang
    • 2
  • Yanfang Zhao
    • 3
  • Lupeng Wu
    • 1
  • Bin Li
    • 1
  1. 1.Department of Hepatobiliary & Pancreatovascular Surgery, Oncologic Center of XiamenFirst Affiliated Hospital of Xiamen UniversityXiamenChina
  2. 2.Testing Center for Occupational HealthShanghai Institute of Occupational Safety and HealthShanghaiChina
  3. 3.Department of Health StatisticsSecond Military Medical UniversityShanghaiChina

Personalised recommendations